Qian CN, Zhang W, Xu RH. Defeating cancer: the 150 most important questions in cancer research and clinical oncology. Chin J Cancer. 2016;35:104.
Article
PubMed
PubMed Central
Google Scholar
Wee JT, Poh SS. The most important questions in cancer research and clinical oncology. Question 1. Could the vertical transmission of human papilloma virus (HPV) infection account for the cause, characteristics, and epidemiology of HPV-positive oropharyngeal carcinoma, non-smoking East Asian female lung adenocarcinoma, and/or East Asian triple-negative breast carcinoma? Chin J Cancer. 2017;36:13.
Article
PubMed
PubMed Central
Google Scholar
Venniyoor A. The most important questions in cancer research and clinical oncology—Question 2–5. Obesity-related cancers: more questions than answers. Chin J Cancer. 2017;36:18.
Article
PubMed
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 6–14. Chin J Cancer. 2017;36:33.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 15–24. Chin J Cancer. 2017;36:39.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 25–30. Chin J Cancer. 2017;36:42.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 31–39. Chin J Cancer. 2017;36:48.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 40–49. Chin J Cancer. 2017;36:55.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 50–56. Chin J Cancer. 2017;36:69.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 57–66. Chin J Cancer. 2017;36:79.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 67–75. Chin J Cancer. 2017;36:86.
Article
PubMed Central
Google Scholar
Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2(11):862–71.
Article
CAS
PubMed
Google Scholar
Kayacan O, et al. Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol. 2006;29(4):328–35.
Article
CAS
PubMed
Google Scholar
Oliff A. The role of tumor necrosis factor (cachectin) in cachexia. Cell. 1988;54(2):141–2.
Article
CAS
PubMed
Google Scholar
Fukawa T, et al. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nat Med. 2016;22(6):666–71.
Article
CAS
PubMed
Google Scholar
Qian CN. The rationale for preventing cancer cachexia: targeting excessive fatty acid oxidation. Chin J Cancer. 2016;35(1):67.
Article
PubMed
PubMed Central
Google Scholar
Currow DC, Skipworth RJ. The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia. Future Oncol. 2017;13(20):1767–83.
Article
CAS
PubMed
Google Scholar
McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15(2):223–43.
Article
PubMed
PubMed Central
Google Scholar
Ozdemir BC, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2015;28(6):831–3.
Article
CAS
PubMed
Google Scholar
Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res. 2014;20(8):2072–9.
Article
CAS
PubMed
Google Scholar
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.
Article
CAS
PubMed
Google Scholar
Plum SM, et al. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model. Clin Cancer Res. 2003;9(12):4619–26.
CAS
PubMed
Google Scholar
Cao Y. Off-tumor target–beneficial site for antiangiogenic cancer therapy? Nat Rev Clin Oncol. 2010;7(10):604–8.
Article
CAS
PubMed
Google Scholar
Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2(10):795–803.
Article
CAS
PubMed
Google Scholar
Yang Y, et al. The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages. Nat Commun. 2016;7:11385.
Article
CAS
PubMed
PubMed Central
Google Scholar
Aprahamian M, Bour G, Akladios CY, Fylaktakidou K, Greferath R, Soler L, et al. Myo-InositolTrisPyroPhosphate treatment leads to HIF-1alpha suppression and eradication of early hepatoma tumors in rats. Chem bio chem Eur J Chem Biol. 2011;12(5):777–83.
Article
CAS
Google Scholar
Fylaktakidou KC, Lehn JM, Greferath R, Nicolau C. Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin. Bioorg Med Chem Lett. 2005;15(6):1605–8.
Article
CAS
PubMed
Google Scholar
Derbal-Wolfrom L, Pencreach E, Saandi T, Aprahamian M, Martin E, Greferath R, et al. Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2. Oncogene. 2013;32(36):4313–8.
Article
CAS
PubMed
Google Scholar
Limani P, Linecker M, Kachaylo E, Tschuor C, Kron P, Schlegel A, et al. Antihypoxic potentiation of standard therapy for experimental colorectal liver metastasis through myo-inositol trispyrophosphate. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22(23):5887–97.
Article
CAS
Google Scholar
Rossi M, Lipworth L, Maso LD, Talamini R, Montella M, Polesel J, et al. Dietary glycemic load and hepatocellular carcinoma with or without chronic hepatitis infection. Ann Oncol Off J Eur Soc Med Oncol. 2009;20(10):1736–40.
Article
CAS
Google Scholar
Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293(2):194–202.
Article
CAS
PubMed
Google Scholar
Healy ME, Chow JD, Byrne FL, Breen DS, Leitinger N, Li C, et al. Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine. J Hepatol. 2015;62(3):599–606.
Article
CAS
PubMed
Google Scholar
Dehghan M, Mente A, Zhang X, Swaminathan S, Li W, Mohan V, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet. 2017;390:2050–62.
Article
CAS
PubMed
Google Scholar
Kachaylo E, Tschuor C, Calo N, Borgeaud N, Ungethum U, Limani P, et al. PTEN down-regulation promotes beta-oxidation to fuel hypertrophic liver growth after hepatectomy in mice. Hepatology. 2017;66(3):908–21.
Article
CAS
PubMed
Google Scholar
Linecker M, Limani P, Kambakamba P, Kron P, Tschuor C, Calo N, et al. Omega-3 fatty acids protect fatty and lean mouse livers after major hepatectomy. Ann Surg. 2017;266(2):324–32.
Article
PubMed
Google Scholar
He XK, Su TT, Si JM, Sun LM. Metformin is associated with slightly reduced risk of colorectal cancer and moderate survival benefits in diabetes mellitus: a meta-analysis. Medicine. 2016;95(7):e2749.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ma SJ, Zheng YX, Zhou PC, Xiao YN, Tan HZ. Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis. Oncotarget. 2016;7(40):66202–11.
PubMed
PubMed Central
Google Scholar